Youjia Biopharma and Buchang Bio Enter Strategic Collaboration to Advance siRNA-based Innovative Therapy Targeting Cardiovascular Diseases
YOUJIA BIO
Nucleic Acid Drug Developer
Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
On May 23, 2024, Youjia (Hangzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as "YOUJIA BIO") and Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (hereinafter referred to as "Buchang Biopharmaceutical") officially signed the "Development Contract for an Innovative Small Interfering RNA (siRNA) Drug Targeting Cardiovascular Indications" in Beijing. YOUJIA BIO granted Buchang Biopharmaceutical exclusive licensing cooperation rights to jointly advance the clinical translation of innovative drugs and open a new chapter in the prevention and treatment of cardiovascular diseases.
Cardiovascular diseases have always been the leading cause of death globally and a major public health issue, according to "China Cardiovascular Health and Disease Report 2022Cardiovascular diseases account for the highest proportion of disease-related deaths among Chinese residents. It is estimated that the number of cardiovascular disease patients in China has reached 330 million, and the prevalence rate is continuously on the rise.
In recent years, the influx of a large number of innovative drugs has provided broad prospects for etiological research, the establishment of new concepts, and the formulation of new diagnostic and treatment methods in the cardiovascular field. Among them, siRNA drugs, as an innovative therapeutic solution that focuses on precise gene regulation, can achieve precise degradation of specific mRNA and block protein synthesis without affecting the original DNA sequence or other gene expressions, offering multiple benefits such as high efficacy, long-lasting effects, safety, and convenience:
Powerful: Optimization and selection of siRNA sequences bring more precise and powerful target gene silencing effects;
Long-acting: An upstream mechanism of action can achieve ultra-long efficacy, while advancements in the delivery system ensure that siRNA is protected from clearance and effectively transferred to the target;
l Safety: The designed and chemically modified siRNA sequences can reduce their off-target toxicity or other toxic effects;
l Convenience: Ultra-long dosing intervals revolutionize traditional chronic disease management models, enhancing patient compliance;
Mature target selection and gene sequence design, excellent chemical modification technology, and delivery systems are key links to achieve the clinical transformation of siRNA, and they are also one of the R&D challenges faced by many pharmaceutical companies in China. As a representative company in China for siRNA drug development, YOUJIA BIO has a complete nucleic acid drug development platform. It has built an intelligent NDDS system for target selection and sequence design, the third-generation CMS3 chemical modification technology, and a diversified delivery system with independent intellectual property rights that supports various administration methods and targeting, including CPNP, PNAC, and LNP, making long-term preparations to enhance the clinical transformation of siRNA drugs and develop the best possible siRNA.
Promote Cooperation, Share and Win Together, and Boost the Takeoff of China-Produced Innovative Drugs
At the signing ceremony, Dr. Yang Chun, Chairman of Buchang Bio, stated that YOUJIA BIO, as a representative company in China's nucleic acid drug research and development, has demonstrated its technical strength and innovative achievements in the industry. For instance, the company’s self-developed anti-liver fibrosis siRNA drug has successfully applied to the U.S. FDA for an Investigational New Drug (IND) application, fully demonstrating its outstanding R&D capabilities in the siRNA field. It is believed that through this collaboration, both parties will optimize clinical research management models and advance and lead a new era of chronic cardiovascular disease treatment with siRNA drugs as the main strategy.
Youjia (Hangzhou) Biomedical Technology Co., Ltd. ("YOUJIA BIO") was co-founded by a team of multiple returned overseas PhDs and professionals with rich industrial experience. Located in the Yangtze River Delta International Biomedical Industry Park, Xiaoshan Economic and Technological Development Zone, Hangzhou, Zhejiang Province, the company owns nearly 1,500 square meters of molecular biology and chemistry laboratories. With the starting point of meeting clinical needs, YOUJIA BIO is committed to developing affordable innovative drugs for the general public. Its product pipeline covers areas such as antiviral, anti-fibrosis, and cardiovascular diseases. Currently, the company has established a mature full-process development platform for nucleic acid drugs, including the NDDS intelligent design system for nucleic acid drugs, drug evaluation systems, delivery systems, and a CMC platform for nucleic acid drugs.
Source: YOUJIA BIO